COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
The recent expansion of COVID-19 booster shots for certain adult Americans means that millions more people are now eligible to seek extra protection against the deadly virus.
The Food and Drug Administration authorized Pfizer’s COVID-19 vaccine for pediatric use, moving the issue of administration to the Centers for Disease Control and Prevention for consideration.
In a study of over 7,000 adults hospitalized with COVID-19 symptoms, unvaccinated patients with prior SARS-CoV-2 infection were five times more likely to have laboratory-confirmed COVID-19 than were patients fully vaccinated against COVID-19 and no previous infection, the Centers for Disease…
As a Centers for Disease Control and Prevention advisory committee prepares to consider expanding COVID-19 vaccine eligibility to children aged 5-11, the AHA, American Academy of Pediatrics and Children’s Hospital Association will webcast a panel discussion Nov. 8 at 2 p.m. ET on how pediatricians…
A Food and Drug Administration advisory committee voted to recommend an emergency use authorization of Pfizer’s COVID-19 vaccine for children age 5-11.
In a study comparing 6.4 million COVID-19 vaccine recipients with 4.6 million demographically similar unvaccinated persons, recipients of the Pfizer, Moderna or Janssen vaccines had lower non-COVID-19 mortality risk than did the unvaccinated comparison groups, the Centers for Disease Control and…
The Centers for Medicare & Medicaid Services released Medicare Part B billing codes and payment allowances for reporting and administering single booster doses of the Moderna and Johnson & Johnson COVID-19 vaccines to eligible adults as authorized Oct. 22 by the Food and Drug Administration…
The recorded webinar identifies the value of communication in a team-based setting introducing the evidence-based set of tools.
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response and Food and Drug Administration extended the shelf life for the monoclonal antibody therapy etesevimab, which currently must be administered with bamlanivimab.
Centers for Disease Control and Prevention Director Rochelle Walensky, M.D., recommended a single COVID-19 vaccine booster dose at least six months after completing an initial mRNA COVID-19 vaccine series for certain individuals at risk for severe COVID-19, as proposed by her agency’s Advisory…